POU6F2

Across TCGA pan-cancer cohorts, POU6F2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POU6F2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher POU6F2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated POU6F2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where POU6F2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.424	.011	8	view →
PDAC	OS	Median	III,IV	0.466	0.976	.007	5	view →
HNSC	DFS	Median	III,IV	0.511	0.827	.037	4	view →
LUAD	DFS	Tertile	III,IV	1.000	0.634	.027	3	view →
LSCC	DFS	Median	II,III,IV	0.609	0.818	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POU6F2–CCRCC (DFS)

Open the CCRCC breakdown →